Here's Why Cara Therapeutics Slipped 11.4% in March [The Motley Fool]
Cara Therapeutics, Inc. (CARA)
Last cara therapeutics, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.caratherapeutics.com/investor-relations
Company Research
Source: The Motley Fool
It looks like the quarters ahead could get a little more expensive than expected. Cory Renauer ( TMFang4apples ) Apr 6, 2018 at 1:43PM What happened Shares of Cara Therapeutics, Inc. ( NASDAQ:CARA ) , a clinical-stage biotech focused on non-opioid pain relief, fell 11.4% in March, according to data from S&P Global Market Intelligence . Along with a fourth-quarter earnings release, the company laid out plans for the late-stage development of its lead drug candidate that could get a bit more expensive than investors may have hoped. So what As a pre-commercial biotech, Cara doesn't have any significant revenue to fund clinical trials. Management thinks the $93 million cash balance on the books at the end of 2017 will be enough to keep operations humming along into 2019, but investors weren't feeling so confident after the company's latest earnin
Show less
Read more
Impact Snapshot
Event Time:
CARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CARA alerts
High impacting Cara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CARA
News
- Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024GlobeNewswire
- Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Uremic Pruritus Pipeline Insight 2024, Featuring Key Players Cara Therapuetics and Lumosa Therapeutics, and Key Emerging Drugs Cara Therapeutics CR845 and Lumos Therapeutics' LT 5001 [Yahoo! Finance]Yahoo! Finance
- Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.MarketBeat
- Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
CARA
Earnings
- 3/4/24 - Beat
CARA
Sec Filings
- 5/6/24 - Form 4
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form ARS
- CARA's page on the SEC website